Type 2 diabetes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 66
• SGLT2 41
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• mTOR 0
• NRF2 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• STK11 0
• IL-17 1
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Bridging Chronobiology and Physiology through Expert Training (ChronoBridge)

  Ecole Polytechnique Federale de Lausanne· Lausanne, Switzerland· EU contribution €3,885,022· until Dec 2030· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  AI-Powered and Robot-Assisted Opto-Acoustic Evaluation of Systemic Microangiopathy for Ulcer Healing Outcomes in Type 2 Diabetes (ARETEOS)

  Universitatsklinikum Erlangen· Erlangen, Germany· EU contribution €1,499,068· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  First-in-man beta-cell regeneration for causal type 2 diabetes therapy (BetaProtect)

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Apr 2028

5 of 59 running projects, newest first. Listed amounts together: €152.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor

  NCT07929233· Portuguese Oncology Institute, Coimbra· Source

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Source

• A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

  NCT07775404· AstraZeneca· Source

• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Eli Lilly and Company· Source

• A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

  NCT07915609· Pfizer· Source

• A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Eli Lilly and Company· Source

• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  NCT07654374· Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics· Source

• GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Source

• Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis

  NCT06715514· Lia Bally· Source

• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Pfizer· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 26
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 113
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 186
• Machine Learning 195
• Deep Learning 32
• Cohort Studies 1111
• Genome-Wide Association Study 315

• Colchicine use was associated with reduced all-cause mortality in patients with diabetic gout without prior coronary artery disease: A propensity-matched nationwide cohort study.

  PLoS One, Nov 2026

• Sodium-glucose cotransporter 2 inhibitors and risk of self-harm in patients with type 2 diabetes mellitus: an active comparator, new user cohort study in two independent cohorts.

  Psychol Med, Nov 2026

• Severe Infection Outcomes With SGLT2 Versus DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Active-Comparator Meta-Analysis of Real-World Cohorts.

  Endocrinol Diabetes Metab, Nov 2026

• Longitudinal Repeated Protein Measurements in a Multiethnic Cohort Identify Novel Diabetes Biomarkers That Reveal Unique Disease Pathways.

  Diabetes, Nov 2026

• GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data.

  Lancet Psychiatry, Nov 2026

• Incident transient ischemic attack and subsequent cardiovascular events and mortality in patients with newly diagnosed type 2 diabetes: a population-based cohort study.

  Front Endocrinol (Lausanne), Oct 2026

• Association between atherogenic index of plasma and microvascular complications in patients with type 2 diabetes achieving low-density lipoprotein cholesterol targets: a real-world cohort study.

  J Glob Health, Oct 2026

• Serial fibrosis-4 variability and longitudinal patterns are associated with incident heart failure in type 2 diabetes: a 24-month landmark cohort study.

  Front Endocrinol (Lausanne), Oct 2026

• Impact of diabetic foot ulcers on mortality risk: Lessons from a 35-year Brazilian cohort followed at an association of people living with diabetes.

  Arch Endocrinol Metab, Oct 2026

• Life's Essential 8 score and arterial stiffness in patients with type 2 diabetes.

  Arch Endocrinol Metab, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.